ABMGG Medical Biochemical Genetics study materials
ABMGG Medical Biochemical Genetics study resources

ABMGG Medical Biochemical Genetics: Biochemical Genetics

ABMGG Medical Biochemical Genetics · Work through your exam, one topic at a time.

All guide sections

Biochemical Genetics

Biochemical Genetics

This domain tests the core principles of how genetic defects produce metabolic disease: enzyme kinetics, pathway logic, and the biochemical consequences of a block. Candidates must understand concepts such as Km and Vmax, the effect of mutations on enzyme activity (loss-of-function, gain-of-function, dominant-negative), and how these relate to residual enzyme activity and clinical severity. You should be able to predict the accumulation of upstream metabolites and depletion of downstream products when a step is impaired, and recognize that alternate pathways may produce characteristic byproducts (e.g., galactitol in galactosemia).

Traps in questions often involve confusing the primary defect with secondary biochemical changes, or assuming that all mutations in a gene cause the same biochemical phenotype. Remember that cofactor defects (e.g., biotin, cobalamin) can affect multiple enzymes, and that enzyme activity may be normal in some tissues but deficient in others. Also, be careful with disorders where the accumulated substrate is not the direct cause of toxicity (e.g., phenylketonuria: phenylalanine is toxic, but the defect is in phenylalanine hydroxylase).

A useful rule of thumb: when you see a metabolic block, think "upstream accumulates, downstream depletes, alternate routes produce unusual metabolites." For example, in classic galactosemia (GALT deficiency), galactose-1-phosphate accumulates, and galactitol is formed via aldose reductase, causing cataracts. This triad helps answer questions about expected lab findings and complications.

Key Points

  • Enzyme kinetics: Km reflects substrate affinity; Vmax reflects maximal rate; mutations can alter either.
  • Pathway logic: enzyme block → upstream accumulation, downstream deficiency, alternate metabolite production.
  • Residual enzyme activity often correlates with clinical severity (e.g., mild vs severe PKU).
  • Cofactor defects can mimic multiple enzyme deficiencies.
  • Tissue-specific expression can cause discordant biochemical and clinical findings.